- Telehealth Visits
- Insurance plan information
Emma Samelson-Jones, MD
Psychiatry- Telehealth Visits
- Insurance plan information
Psychiatry Mission Bay
Emma Samelson-Jones, MD
PsychiatryPsychiatry Mission Bay
- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Emma Samelson-Jones is a psychiatrist who cares for adults with a wide variety of mental health concerns, including anxiety, depression, bipolar disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), psychosis and substance use disorders. Her practice is embedded in a primary care clinic, allowing patients to receive mental and physical health care in the same location.
Samelson-Jones earned her medical degree at UCSF. She completed a residency in psychiatry and a fellowship in public psychiatry at Columbia University.
Education & training
Board certification
- Psychiatry, American Board of Psychiatry and Neurology
Fellowship
- Psychiatry, Columbia University Medical Center-Psychiatry GME
Residency
- Psychiatry, New York Presbyterian Hospital/Columbia University
Degree
- MD, UCSF School of Medicine
My expertise
Specialties
Locations
My research
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.